Rolvedon™ (eflapegrastim-xnst) – New drug approval
September 9, 2022 - Spectrum Pharmaceuticals announced the FDA approval of Rolvedon (eflapegrastim-xnst), to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Top